Plavix Patent Litigation to Resume, Sanofi Exec Says

Law360, New York (August 2, 2006, 12:00 AM EDT) -- Patent litigation between Sanofi-Aventis S.A., Bristol-Myers Squibb and Apotex Corp. over a generic version of the blood thinner Plavix will be reinstated, Sanofi Chief Financial Officer Jean-Claude Leroy said on Wednesday.

The comment was made to analysts after the company reported its second quarter results, Dow Jones reported.

Sanofi-Aventis, the distributor of Plavix in Europe, and Bristol-Myers, which sells the drug in the United States, reached a settlement with Apotex Corp. in March in which Apotex agreed to refrain from making generic Plavix in exchange for...
To view the full article, register now.